M&A vibes amid earnings season; CAR-T beyond cancer; Lilly doubles down on obesity; Two consequential FDA approvals; and more
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.
What a week — it honestly felt more like a month. I can almost guarantee that you will read something in this issue that you overlooked the past few days. As always, we welcome your feedback on the format and content of the report. Just shoot me an email.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 170,200+ biopharma pros reading Endpoints daily — and it's free.